文献类型：期刊文献

英文题名：In Vivo Biodistribution and Anti-Tumor Efficacy Evaluation of Doxorubicin and Paclitaxel-Loaded Pluronic Micelles Decorated with c(RGDyK) Peptide

作者：Chen, Yanzuo[1,2,3,4];Zhang, Wei[2,3,5];Huang, Yukun[1];Gao, Feng[1];Fang, Xiaoling[2,3]

机构：[1]E China Univ Sci & Technol, Sch Pharm, Dept Pharmaceut, Shanghai 200237, Peoples R China;[2]Fudan Univ, Sch Pharm, Key Lab Smart Drug Delivery, Minist Educ, Shanghai 201203, Peoples R China;[3]Fudan Univ, Sch Pharm, PLA, Shanghai 201203, Peoples R China;[4]Fudan Univ, State Key Lab Mol Engn Polymers, Dept Macromol Sci, Shanghai 200433, Peoples R China;[5]Eastern Virginia Med Sch, Dept Obstet & Gynecol, CONRAD, Arlington, VA 22209 USA

年份：2016

卷号：11

期号：3

外文期刊名：PLOS ONE

收录：;WOS:【SCI-EXPANDED(收录号:WOS:000371434500076)】；

基金：This work was supported by the National Natural Science Foundation of China (30901862) (http://www.nsfc.gov.cn/publish/portal1/) (YC) who had a role in the decision to publish, preparation of the manuscript; the Postdoctoral Science Foundation of China (2014M550222) (http://jj.chinapostdoctor.org.cn/V1/Program1/Default.aspx) (YC) who had a role in the study design, data collection and analysis, decision to publish, preparation of the manuscript; the Shanghai Postdoctoral Sustentation Fund (14R21410500) (http://www.stcsm.gov.cn/) (YC) who had a role in the study design, data collection and analysis, decision to publish, preparation of the manuscript; the National Basic Research Program of China (2013CB932500) (http://www.most.gov.cn/) (XF) who had a role in the study design, data collection and analysis, decision to publish, preparation of the manuscript; and the Fundamental Research Funds for the Central Universities (22A201514055 ECUST) (http://www.moe.gov.cn/) (FG) who had a role in the decision to publish.

语种：英文

摘要：The treatment of squamous carcinoma, especially multidrug resistance (MDR) tumors, represents one of the most formidable challenges in oncology. In this study, integrin-mediated Pluronic-based micellar system (c(RGDyK)-FP-DP) was proposed as a drug delivery system to enhance the in vivo anti-tumor efficacy in MDR human squamous carcinoma (KBv)bearing. Following the recognition by integrin proteins express on the cell surface, cellular uptake and in vitro anti-tumor efficacy of c(RGDyK)-FP-DP were better than conventional PF-DP in KBv cells. The tumor homing specificity and further in vivo anticancer efficacy of c (RGDyK)-FP-DP were performed using subcutaneous KBv tumor-bearing mice model, respectively. Compared with PF-DP, c(RGDyK)-FP-DP demonstrated more drug accumulation in tumor and relatively less drug accumulation in heart, and an extended median survival time in the KBv tumor-bearing mice model. Furthermore, preliminary in vivo subacute toxicity evaluation was also conducted by the measurement of histopathology, blood cell counts and clinical biochemistry parameters. Results showed that no obvious toxicity was observed to the hematological system or heart after a series of intravenous administration of c(RGDyK)-FP-DP. In conclusion, our results suggested that c(RGDyK) peptide conjugated Pluronic micelles could be a promising vehicle for enhancing the treatment of MDR human squamous carcinoma.